Mark Harbeck, MD
Dermatology · Novi, MINPI 1578665527
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,451 of the $4,975 with a category attached, or 89.5%. 30 manufacturers reported payments, led by Johnson & Johnson at 36.2% of the total.
Across 263 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$549
- Pfizer$337
- Dermavant Sciences, Inc.$330
- Novartis$301
- Sun Pharmaceutical Industries Inc.$170
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,45189%
- Education$52411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 93 | $1,802 |
| AbbVie | 31 | $549 |
| Pfizer | 18 | $337 |
| Dermavant Sciences, Inc. | 21 | $330 |
| Novartis | 14 | $301 |
| Sun Pharmaceutical Industries Inc. | 10 | $170 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| Organogenesis Inc. | 4 | $128 |
| LEO Pharma Inc. | 6 | $116 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $114 |
| Almirall LLC | 2 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Sanofi | 5 | $87 |
| UCB, Inc. | 3 | $85 |
| Arcutis Biotherapeutics, Inc. | 4 | $74 |
| Lilly USA, LLC | 4 | $68 |
| Organon | 4 | $66 |
| Journey Medical Corporation | 4 | $65 |
| Botanix SB Inc | 3 | $57 |
| Amgen | 3 | $54 |
| Galderma Laboratories, L.p. | 3 | $48 |
| VYNE Pharmaceuticals Inc. | 2 | $47 |
| Boehringer Ingelheim | 1 | $28 |
| Biofrontera Inc. | 1 | $19 |
| Aclaris Therapeutics, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Dermira, Inc. | 1 | $18 |
| Strata Skin Sciences, Inc. | 1 | $14 |
| Sandoz | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $8 |
How this compares
$4,975 in reported general payments places this provider in the 60th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $44,385 |
| Metronidazole | 48 | $3,502 |
| Calcipotriene | 15 | $2,611 |
| Ketoconazole | 86 | $2,263 |
| Tacrolimus | 19 | $2,149 |
| Acitretin | 11 | $1,845 |
| Triamcinolone Acetonide | 169 | $1,576 |
| Doxycycline Hyclate | 45 | $1,543 |
| Clobetasol Propionate | 55 | $1,478 |
| Fluorouracil | 27 | $1,418 |
| Ammonium Lactate | 47 | $1,225 |
| Fluocinonide | 26 | $1,091 |
| Clindamycin Phosphate | 24 | $925 |
| Desonide | 39 | $789 |
| Imiquimod | 41 | $781 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Novi
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.